Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Carbone Dioxide (CO2) Laser System in Treatment of Female Stress Urinary Incontinence. (CO2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02981654
Recruitment Status : Unknown
Verified December 2016 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : December 5, 2016
Last Update Posted : December 6, 2016
Sponsor:
Collaborators:
The Baruch Padeh Medical Center, Poriya
Kaplan Medical Center
Information provided by (Responsible Party):
Sheba Medical Center

Brief Summary:

This is a prospective, open-label, multi-center, non-comparative study that will be conducted on female subjects between 30 and 75 years of age, diagnosed with stress urinary incontinence (SUI).

Following the screening period, including urodynamic assessment to confirm SUI, each subject will undergo three FemiLiftTM treatment sessions, and will be followed up for a period of one year. The main efficacy endpoint in this study is defined as significant improvement (score of 6 or 7) in the urinary incontinence measured with PGI-I score at the 6 months visit. Various subjective and objective measures of incontinence severity, quality of life, sexual function and tissue effects will be performed at follow up.


Condition or disease Intervention/treatment Phase
Female Stress Urinary Incontinence Device: Alma Lasers Pixel carbon dioxide laser system Not Applicable

Detailed Description:

Improvement in SUI symptoms as measured by the following parameters:

Objective parameters:

  • Change from baseline in 3 days Urinary Diary - at 1, 2, 6 and 12 months:

    • Number of incontinence episodes per day
    • Number of pads used per day
  • Change from baseline in 1 hour pad test 1, 2, 6 and 12 months
  • Change from baseline as assessed with Vaginal Biopsy

Subjective parameters:

  • Patient Global Impression of Severity (PGI-S) - 4-point Likert scale - at screening, 1, 2, 6 and 12 months
  • Change from baseline in Pelvic Floor Distress Inventory Questionnaire (PFDI) - at 1, 2, 6 and 12 months
  • Change from baseline in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ) - at 1, 2, 6 and 12 months
  • Change from baseline in Pelvic Floor Impact Questionnaire (PFIQ) - at 1, 2, 6 and 12 months

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open-Label, Multi-Center, Non- Comparative Study to Assess the Safety and Efficacy of CO2 Laser System (FemiLiftTM) in the Treatment of Stress Urinary Incontinence (SUI) in Female Subjects.
Study Start Date : December 2016
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Femilift treatment

The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.

Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length.

Device: Alma Lasers Pixel carbon dioxide laser system
The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.




Primary Outcome Measures :
  1. Success Rate - SUI Symptom Improvement [ Time Frame: 6 months ]
    Success rate - defined as an improvement in SUI symptoms as a score or 6 or 7 measured by the Patient Global Impression of Improvement (PGI-I) - 7-point Likert scale - at the 6 months visit


Secondary Outcome Measures :
  1. Urinary Diary [ Time Frame: 12 months ]

    Change from baseline in 3 days Urinary Diary - at 1, 2, 6 and 12 months post first treatment:

    • Number of incontinence episodes per day

  2. 1 hour pad test [ Time Frame: 12 months ]
    Change from baseline in 1 hour pad test at 1, 2, 6 and 12 months post first treatment

  3. Vaginal Biopsy [ Time Frame: 12 months ]
    Sample will be obtained from the vaginal mucosa 2 cm inside the introitus on the lateral vaginal wall.

  4. PGI-S [ Time Frame: 12 months ]
    Change from baseline in Patient Global Impression of Severity (PGI-S) over time

  5. PFDI [ Time Frame: 12 months ]
    Change from baseline in Pelvic Floor Distress Inventory Questionnaire (PFDI) over time

  6. PISQ [ Time Frame: 12 months ]
    Change from baseline in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ) over time

  7. PFIQ [ Time Frame: 12 months ]
    Change from baseline in Pelvic Floor Impact Questionnaire (PFIQ) over time

  8. Safety Endpoint assessed by the rate of serious device related adverse events [ Time Frame: 12 months ]
    The rate of serious device related adverse events reported during the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Females between 30 and 75 years of age
  • Provided written Informed Consent
  • Patients with mild to moderate stress urinary incontinence (SUI) [according to the severity index developed by Sandvik]
  • Patients with mixed urinary incontinence, while the predominant symptoms are stress related, may also be enrolled
  • Normal Papanicolaou smear (up to 1 year prior to screening)
  • Negative urine culture
  • Vaginal canal, introitus and vestibule free of injuries and bleeding
  • Positive urinary stress test (Urine leakage is demonstrated while the patient is examined with full bladder in lithotomy position, and asked to perform 3 strong coughs).

Exclusion Criteria:

  • Positive pregnancy test
  • Planned pregnancy within the next year
  • Severe prolapse (POP>= grade 3)
  • Use of photosensitive drugs
  • Injury or/and active infection in the treatment area
  • Active vaginal infection
  • human papillomavirus/herpes simplex virus
  • Undiagnosed vaginal bleeding
  • Urge or overflow incontinence
  • Patients who are on antidepressants, or α-adrenergic and anticholinergic medications
  • Patients with immune system diseases.
  • Patients with allergic reaction to laser.
  • Patient under treatment with photosensitivity side effects medication.
  • Obese women (BMI >30)
  • Patient unable to follow post treatment instructions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02981654


Contacts
Layout table for location contacts
Contact: Yair Leopld 972-54-4847271 Yair.Leopold@almasurgical.com

Sponsors and Collaborators
Sheba Medical Center
The Baruch Padeh Medical Center, Poriya
Kaplan Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Menachem Alcalay, MD Head, Urogynecology Unit, Chaim Sheba Medical Center

Layout table for additonal information
Responsible Party: Sheba Medical Center
ClinicalTrials.gov Identifier: NCT02981654     History of Changes
Other Study ID Numbers: 2092-15-SMC
First Posted: December 5, 2016    Key Record Dates
Last Update Posted: December 6, 2016
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Enuresis
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders